Home

helps physicians and healthcare professionals

Erectile Dysfunction

helps physicians and healthcare professionals

Doctor123.org

helps physicians and healthcare professionals

Erythema Multiforme, Emergency Medicine


Basics


Description


  • A rash caused by a hypersensitivity reaction:
    • May occur in response to various medications, infections, or other illness
  • Erythema multiforme (EM) minor:
    • Typical target lesions
    • Edematous papules
    • Usually distributed peripherally
    • Benign, self-limited rash generally not associated with acute, serious illness
  • EM major
    • Also called bullous EM
    • Target lesions
    • Edematous papules
    • Also with peripheral distribution
    • Involves 1 or more mucous membranes
    • <10% total body surface area of epidermal detachment
  • Differentiate from:
    • Stevens-Johnson syndrome (SJS):
      • Also <10% TBSA epidermal detachment
      • Often widespread blisters over trunk and face
      • Mucosal involvement
    • Toxic epidermal necrolysis (TEN)
      • >30% TBSA epidermal detachment
    • EM is now considered a different entity from SJS and EM
  • Most often affects children and young adults (>50% younger than 20 yr)
  • Males are affected more often than females.

Etiology


  • Hypersensitivity reaction, probably transient autoimmune defect
  • Herpes simplex virus (HSV) is the most common precipitant (>70%).
  • Other causes include:
    • Idiopathic
    • Medications
      • Penicillin
      • Sulfur based
      • Phenytoin
      • Barbiturates
      • NSAIDs
    • Vaccines
      • Diphtheria-tetanus
      • Hepatitis B
      • Smallpox
    • Malignancy
    • Infection
      • HIV
      • CMV
      • Hepatitis C
      • Mycoplasma infections

Diagnosis


Signs and Symptoms


History
  • Prodrome: Infrequent systemic symptoms (mild fever/malaise), antecedent HSV in most cases (within 3 wk)
  • Usually not associated with severe systemic illness

Physical Exam
Characteristic rash:  
  • Lesions:
    • Symmetric dull red macules and papules
    • Evolve into round, well-demarcated target lesions with central clearing
    • No epidermal necrosis with EM minor
  • Multiforme refers to the evolution of the rash through various stages at different times.
  • Distribution:
    • Extremities
    • Dorsal hands and feet
    • Extensor surfaces
    • Elbows and knees.
  • 1 of the few rashes that may involve palms and soles
  • Spread: From extremities toward trunk
  • Mucosal involvement: Minor blistering or erosions of 1 mucosal surface (lips/mouth)
  • Duration: Usually 1-4 wk, but may become chronic or recurrent

Essential Workup


Complete history and physical exam, with special attention to the skin, genitourinary system, recent infectious symptoms, and recent medications  

Diagnosis Tests & Interpretation


Lab
No specific lab tests needed  
Imaging
No specific imaging is helpful.  
Diagnostic Procedures/Surgery
  • Skin biopsy reveals mononuclear cell infiltrate around upper dermal blood vessels, without leukocytoclastic vasculitis and necrosis of epidermal keratinocytes.
  • Biopsy is not necessary in most cases.

Differential Diagnosis


  • Systemic lupus erythematosus
  • Fixed drug eruption
  • Pityriasis rosea
  • Secondary syphilis
  • Erythema migrans
  • Urticaria
  • SJS
  • TEN
  • Vasculitis
  • Viral exanthem

Treatment


Pre-Hospital


Not contagious and does not require isolation or postexposure prophylaxis for exposed personnel  

Initial Stabilization/Therapy


Generally benign and self-limited, requiring no initial stabilization  

Ed Treatment/Procedures


  • Attempt to identify, treat, or remove underlying cause or precipitant.
  • Symptomatic: Cool compresses, antipruritics

Medication


  • Antiviral agents:
    • Acute EM
    • Treat within 48 hr of onset
    • May not impact clinical course
      • Acyclovir: 400 mg PO TID
  • Prevention of recurrent EM
    • Acyclovir 400 mg PO BID
    • Valacyclovir 500 mg PO BID
    • Famciclovir 250 mg PO BID
  • Antipruritic agents:
    • Cetirizine (Zyrtec): 10 mg/d (peds: 2.5-5 mg) PO
    • Diphenhydramine: 25-50 mg (peds: 5 mg/kg/24h) PO q6-8h
    • Hydroxyzine: 25 mg PO q6-8h (peds: 2 mg/kg/24h div. q6-8h)
  • Anesthetic for oral lesions
    • Magic mouthwash
  • Oral corticosteroids:
    • Reserved for severe mucosal disease
    • Prednisone 40-60 mg PO QD tapered over 2-3 wk
  • Medium-potency topical corticosteroids:
    • Triamcinolone 1% apply BID-QID
      • Do not use on face or eyelids
  • Low-potency topical corticosteroids
    • For face or intertriginous regions
    • Hydrocortisone 1% apply BID-QID

First Line
  • Topical corticosteroids (low to medium potency)
  • Antipruritics

Second Line
  • Antivirals
  • Oral corticosteroids

Follow-Up


Disposition


Admission Criteria
  • Admission is not needed unless required for another concurrent disorder.
  • Unable to take PO fluids secondary to mucosal lesions

Discharge Criteria
EM is generally a benign disorder that does not require admission.  
Issues for Referral
  • Patients should be referred to a dermatologist if the diagnosis is uncertain or the rash is atypical or severe.
  • Refer immediately to ophthalmologist if ocular involvement

Follow-Up Recommendations


  • Follow-up with primary care physician within 1 wk to assess:
    • Further evaluation of underlying conditions (infection, medications, malignancy, etc.)
    • Progression or resolution of rash
  • Follow-up with a dermatologist within 1 wk if the diagnosis is uncertain.

Pearls and Pitfalls


  • In patients with severe systemic illness, a more serious diagnosis should be considered, such as SJS or TEN.
  • Most patients with EM have underlying HSV infection.
  • Secondary syphilis may produce similar lesions on the palms and soles.
  • Reassure patients that the rash of EM is benign and self-limited.

Additional Reading


  • Dyall-Smith  D. Erythema multiforme. Available at www.dermnetnz.org. Accessed on July 1, 2011.
  • Lamoreux  MR, Sternbach  MR, Hsu  WT. Erythema multiforme. Am Fam Physician.  2006;74:1883-1888.
  • Plaza  J. Erythema multiforme. Available at www.emedicine.com. Accessed on July 29, 2011.
  • Scully  C, Bagan  J. Oral mucosal diseases: Erythema multiforme. Br J Oral Maxillofac Surg.  2008;46:90-95.
  • Sokumbi  O, Wetter  DA. Clinical features, diagnosis, and treatment of erythema multiforme: A review for the practicing dermatologist. Int J Dermatol.  2012;51:889-902.
  • Wetter  DA. Pathogenesis, clinical features, and diagnosis of erythema multiforme. In: Callen  J, ed. UpToDate. Waltham, MA: UpToDate; 2013.
  • Wetter  DA. Treatment of erythema multiforme. In: Callen  J, ed. UpToDate. Waltham, MA: UpToDate; 2013.

See Also (Topic, Algorithm, Electronic Media Element)


  • Herpes
  • Stevens-Johnson Syndrome
  • Toxic Epidermal Necrolysis

Codes


ICD9


  • 695.10 Erythema multiforme, unspecified
  • 695.13 Stevens-Johnson syndrome
  • 695.15 Toxic epidermal necrolysis
  • 695.19 Other erythema multiforme
  • 695.11 Erythema multiforme minor
  • 695.12 Erythema multiforme major
  • 695.14 Stevens-Johnson syndrome-toxic epidermal necrolysis overlap syndrome
  • 695.1 Erythema multiforme

ICD10


  • L51.1 Stevens-Johnson syndrome
  • L51.2 Toxic epidermal necrolysis [Lyell]
  • L51.9 Erythema multiforme, unspecified
  • L51.8 Other erythema multiforme
  • L51.3 Stevens-Johnson synd-tox epdrml necrolysis overlap syndrome

SNOMED


  • 36715001 erythema multiforme (disorder)
  • 73442001 Stevens-Johnson syndrome (disorder)
  • 23067006 Lyells toxic epidermal necrolysis, subepidermal type (disorder)
  • 297942002 Drug-induced erythema multiforme (disorder)
  • 402971008 Erythema multiforme due to mycoplasma infection (disorder)
Copyright © 2016 - 2017
Doctor123.org | Disclaimer